Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 13/20 | 0.63 |
| ▸ | PNP | P00491 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | PI4KA | P42356 | 1/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20782416 | 0.87 | HPRT1 (0.65) | HPRT1PNPADORA2AADORA1 | |
| Fluorouracil SCHEMBL1648475 | 0.84 | HPRT1 (0.48) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL24239249 | 0.83 | HPRT1 (0.63) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL22381490 | 0.82 | HPRT1 (0.63) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL21127947 | 0.82 | HPRT1 (0.68) | HPRT1PNPADORA2A | |
| SCHEMBL22017431 | 0.82 | HPRT1 (0.68) | HPRT1PNPADORA2A | |
| SCHEMBL11258920 | 0.80 | HPRT1 (0.69) | HPRT1PNP | |
| SCHEMBL27670855 | 0.80 | HPRT1 (0.64) | HPRT1PNP | |
| SCHEMBL11254078 | 0.80 | HPRT1 (0.59) | HPRT1PNPADORA2AADORA1 | |
| SCHEMBL27670854 | 0.80 | HPRT1 (0.56) | HPRT1PNPMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728282-B1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| EP-3672601-B1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS | SAREPTA THERAPEUTICS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023167880-A2 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20230123981-A1 | 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF | NOVO NORDISK A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-20230045831-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-21 | — | — | US | disclosed |
| US-20130018018-A1 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS | Epiphany Biosciences ,Inc. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20110152242-A1 | 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists | MERCK SHARP & DOHME LTD. (GB) | 2011-06-23 | — | — | US | disclosed |
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
| EP-1631260-A2 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | Transform Pharmaceuticals, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004078163-A2 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| EP-0073490-B1 | DIHYDROTHIAZOLE-PURINES | Newport Pharmaceuticals International, Inc. (US) | 1986-04-30 | — | — | EP | disclosed |
| US-4510144-A | Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives | NEWPORT PHARMACEUTICALS INTERNATIONAL (US) | 1985-04-09 | — | — | US | disclosed |
| US-4387226-A | VIRICIDES, IMMUNOLOGY | NEWPORT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 1983-06-07 | — | — | US | disclosed |
| EP-0073490-A1 | Dihydrothiazole-purines | Newport Pharmaceuticals International, Inc. (US) | 1983-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | HPRT1 208/4885PNP 354/4885MEN1 1602/4885 |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | HPRT1 248/4885PNP 174/4885MEN1 1845/4885 |
| US-20230045831-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS | PPIP5K2, MTAP, RNGTT | HPRT1 88/4885PNP 25/4885MEN1 1249/4885 |
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | HPRT1 1932/4885PNP 4682/4885MEN1 4509/4885 |
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | STING1, CGAS, TBK1 | HPRT1 556/4885PNP 724/4885MEN1 1520/4885 |
| US-20130018018-A1 | NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS | PNP, TYMP, ENTPD5 | HPRT1 24/4885PNP 1/4885MEN1 2241/4885 |
| US-20110152242-A1 | 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists | NR2C2, NR3C2, NR2E3 | HPRT1 850/4885PNP 3544/4885MEN1 3443/4885 |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | HPRT1 1046/4885PNP 2832/4885MEN1 4674/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | HPRT1 248/4885PNP 174/4885MEN1 1845/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | HPRT1 274/4885PNP 462/4885MEN1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.